JP2002521070A - 可逆的阻害プローブ - Google Patents
可逆的阻害プローブInfo
- Publication number
- JP2002521070A JP2002521070A JP2000562561A JP2000562561A JP2002521070A JP 2002521070 A JP2002521070 A JP 2002521070A JP 2000562561 A JP2000562561 A JP 2000562561A JP 2000562561 A JP2000562561 A JP 2000562561A JP 2002521070 A JP2002521070 A JP 2002521070A
- Authority
- JP
- Japan
- Prior art keywords
- probe
- region
- nucleic acid
- amplification
- sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000523 sample Substances 0.000 title claims description 187
- 230000006965 reversible inhibition Effects 0.000 title claims description 7
- 230000003321 amplification Effects 0.000 claims abstract description 221
- 238000003199 nucleic acid amplification method Methods 0.000 claims abstract description 221
- 150000007523 nucleic acids Chemical class 0.000 claims abstract description 128
- 102000039446 nucleic acids Human genes 0.000 claims abstract description 95
- 108020004707 nucleic acids Proteins 0.000 claims abstract description 95
- 238000006243 chemical reaction Methods 0.000 claims abstract description 89
- 239000003112 inhibitor Substances 0.000 claims abstract description 22
- 230000002401 inhibitory effect Effects 0.000 claims abstract description 14
- 108091034117 Oligonucleotide Proteins 0.000 claims description 107
- 239000002773 nucleotide Substances 0.000 claims description 70
- 125000003729 nucleotide group Chemical group 0.000 claims description 70
- 230000000295 complement effect Effects 0.000 claims description 57
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 claims description 55
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 claims description 55
- 102000004190 Enzymes Human genes 0.000 claims description 54
- 108090000790 Enzymes Proteins 0.000 claims description 54
- 238000013518 transcription Methods 0.000 claims description 47
- 230000035897 transcription Effects 0.000 claims description 47
- 238000000034 method Methods 0.000 claims description 45
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 claims description 40
- 239000003153 chemical reaction reagent Substances 0.000 claims description 34
- RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical compound CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 claims description 34
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 claims description 32
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 claims description 32
- 239000000203 mixture Substances 0.000 claims description 32
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 28
- ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 claims description 24
- 239000001226 triphosphate Substances 0.000 claims description 22
- 235000011178 triphosphate Nutrition 0.000 claims description 22
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 claims description 20
- 102100034343 Integrase Human genes 0.000 claims description 20
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 claims description 19
- 230000000903 blocking effect Effects 0.000 claims description 19
- 229940113082 thymine Drugs 0.000 claims description 17
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 claims description 16
- 229930024421 Adenine Natural products 0.000 claims description 16
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 claims description 16
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 claims description 16
- 229960000643 adenine Drugs 0.000 claims description 16
- 229940104302 cytosine Drugs 0.000 claims description 16
- 125000003835 nucleoside group Chemical group 0.000 claims description 12
- 239000013037 reversible inhibitor Substances 0.000 claims description 12
- UNXRWKVEANCORM-UHFFFAOYSA-N triphosphoric acid Chemical compound OP(O)(=O)OP(O)(=O)OP(O)(O)=O UNXRWKVEANCORM-UHFFFAOYSA-N 0.000 claims description 12
- 229940035893 uracil Drugs 0.000 claims description 12
- -1 2'-methoxyribose Chemical compound 0.000 claims description 11
- 108010028263 bacteriophage T3 RNA polymerase Proteins 0.000 claims description 11
- 101710137500 T7 RNA polymerase Proteins 0.000 claims description 10
- 239000002777 nucleoside Substances 0.000 claims description 10
- 150000004713 phosphodiesters Chemical class 0.000 claims description 8
- 235000000346 sugar Nutrition 0.000 claims description 8
- 239000000758 substrate Substances 0.000 claims description 7
- RYYWUUFWQRZTIU-UHFFFAOYSA-K thiophosphate Chemical compound [O-]P([O-])([O-])=S RYYWUUFWQRZTIU-UHFFFAOYSA-K 0.000 claims description 7
- 125000000217 alkyl group Chemical group 0.000 claims description 6
- YACKEPLHDIMKIO-UHFFFAOYSA-N methylphosphonic acid Chemical compound CP(O)(O)=O YACKEPLHDIMKIO-UHFFFAOYSA-N 0.000 claims description 6
- 125000000714 pyrimidinyl group Chemical group 0.000 claims description 6
- ASJSAQIRZKANQN-CRCLSJGQSA-N 2-deoxy-D-ribose Chemical compound OC[C@@H](O)[C@@H](O)CC=O ASJSAQIRZKANQN-CRCLSJGQSA-N 0.000 claims description 5
- 108010065868 RNA polymerase SP6 Proteins 0.000 claims description 5
- UGQMRVRMYYASKQ-KQYNXXCUSA-N Inosine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(O)=C2N=C1 UGQMRVRMYYASKQ-KQYNXXCUSA-N 0.000 claims description 4
- 229930010555 Inosine Natural products 0.000 claims description 4
- RYYWUUFWQRZTIU-UHFFFAOYSA-N Thiophosphoric acid Chemical class OP(O)(S)=O RYYWUUFWQRZTIU-UHFFFAOYSA-N 0.000 claims description 4
- 239000005549 deoxyribonucleoside Substances 0.000 claims description 4
- 229960003786 inosine Drugs 0.000 claims description 4
- 239000002342 ribonucleoside Substances 0.000 claims description 4
- KQLDDLUWUFBQHP-UHFFFAOYSA-N Cordycepin Natural products C1=NC=2C(N)=NC=NC=2N1C1OCC(CO)C1O KQLDDLUWUFBQHP-UHFFFAOYSA-N 0.000 claims description 3
- PYMYPHUHKUWMLA-LMVFSUKVSA-N Ribose Natural products OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 claims description 3
- HMFHBZSHGGEWLO-UHFFFAOYSA-N alpha-D-Furanose-Ribose Natural products OCC1OC(O)C(O)C1O HMFHBZSHGGEWLO-UHFFFAOYSA-N 0.000 claims description 3
- OFEZSBMBBKLLBJ-BAJZRUMYSA-N cordycepin Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)C[C@H]1O OFEZSBMBBKLLBJ-BAJZRUMYSA-N 0.000 claims description 3
- OFEZSBMBBKLLBJ-UHFFFAOYSA-N cordycepine Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(CO)CC1O OFEZSBMBBKLLBJ-UHFFFAOYSA-N 0.000 claims description 3
- 238000006073 displacement reaction Methods 0.000 claims description 3
- NYHBQMYGNKIUIF-UUOKFMHZSA-N Guanosine Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O NYHBQMYGNKIUIF-UUOKFMHZSA-N 0.000 claims description 2
- 239000003795 chemical substances by application Substances 0.000 claims description 2
- 239000005547 deoxyribonucleotide Substances 0.000 claims description 2
- 125000002637 deoxyribonucleotide group Chemical group 0.000 claims description 2
- 230000006872 improvement Effects 0.000 claims description 2
- 150000003833 nucleoside derivatives Chemical class 0.000 claims 4
- HMFHBZSHGGEWLO-SOOFDHNKSA-N D-ribofuranose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H]1O HMFHBZSHGGEWLO-SOOFDHNKSA-N 0.000 claims 2
- 239000013615 primer Substances 0.000 description 30
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 22
- 230000027455 binding Effects 0.000 description 21
- 102000004169 proteins and genes Human genes 0.000 description 20
- 108090000623 proteins and genes Proteins 0.000 description 20
- 108091093088 Amplicon Proteins 0.000 description 17
- 230000000694 effects Effects 0.000 description 17
- 241000725303 Human immunodeficiency virus Species 0.000 description 16
- 229910052739 hydrogen Inorganic materials 0.000 description 14
- 238000001514 detection method Methods 0.000 description 12
- 239000001257 hydrogen Substances 0.000 description 12
- 108091093037 Peptide nucleic acid Proteins 0.000 description 11
- 241000711549 Hepacivirus C Species 0.000 description 10
- 239000000047 product Substances 0.000 description 9
- 230000008901 benefit Effects 0.000 description 8
- 230000001965 increasing effect Effects 0.000 description 8
- 108020004414 DNA Proteins 0.000 description 7
- 238000009396 hybridization Methods 0.000 description 7
- 238000003786 synthesis reaction Methods 0.000 description 7
- 108700039691 Genetic Promoter Regions Proteins 0.000 description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- 230000015572 biosynthetic process Effects 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- 239000000872 buffer Substances 0.000 description 5
- 239000006227 byproduct Substances 0.000 description 5
- 238000012986 modification Methods 0.000 description 5
- 230000004048 modification Effects 0.000 description 5
- RXNXLAHQOVLMIE-UHFFFAOYSA-N phenyl 10-methylacridin-10-ium-9-carboxylate Chemical compound C12=CC=CC=C2[N+](C)=C2C=CC=CC2=C1C(=O)OC1=CC=CC=C1 RXNXLAHQOVLMIE-UHFFFAOYSA-N 0.000 description 5
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 4
- 125000004122 cyclic group Chemical group 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 238000007834 ligase chain reaction Methods 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 230000007246 mechanism Effects 0.000 description 4
- 238000003752 polymerase chain reaction Methods 0.000 description 4
- 238000006116 polymerization reaction Methods 0.000 description 4
- 108091033319 polynucleotide Proteins 0.000 description 4
- 102000040430 polynucleotide Human genes 0.000 description 4
- 239000002157 polynucleotide Substances 0.000 description 4
- 238000011533 pre-incubation Methods 0.000 description 4
- 230000035945 sensitivity Effects 0.000 description 4
- 102000053602 DNA Human genes 0.000 description 3
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 3
- 239000010432 diamond Substances 0.000 description 3
- 230000002708 enhancing effect Effects 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 2
- 241000713838 Avian myeloblastosis virus Species 0.000 description 2
- WSNMPAVSZJSIMT-UHFFFAOYSA-N COc1c(C)c2COC(=O)c2c(O)c1CC(O)C1(C)CCC(=O)O1 Chemical compound COc1c(C)c2COC(=O)c2c(O)c1CC(O)C1(C)CCC(=O)O1 WSNMPAVSZJSIMT-UHFFFAOYSA-N 0.000 description 2
- 108091035707 Consensus sequence Proteins 0.000 description 2
- 108060002716 Exonuclease Proteins 0.000 description 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- 101710203526 Integrase Proteins 0.000 description 2
- 241000713869 Moloney murine leukemia virus Species 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- 108091081021 Sense strand Proteins 0.000 description 2
- 229920004890 Triton X-100 Polymers 0.000 description 2
- HAXFWIACAGNFHA-UHFFFAOYSA-N aldrithiol Chemical compound C=1C=CC=NC=1SSC1=CC=CC=N1 HAXFWIACAGNFHA-UHFFFAOYSA-N 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- SUYVUBYJARFZHO-RRKCRQDMSA-N dATP Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-RRKCRQDMSA-N 0.000 description 2
- SUYVUBYJARFZHO-UHFFFAOYSA-N dATP Natural products C1=NC=2C(N)=NC=NC=2N1C1CC(O)C(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-UHFFFAOYSA-N 0.000 description 2
- HAAZLUGHYHWQIW-KVQBGUIXSA-N dGTP Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 HAAZLUGHYHWQIW-KVQBGUIXSA-N 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 229940125532 enzyme inhibitor Drugs 0.000 description 2
- 239000002532 enzyme inhibitor Substances 0.000 description 2
- 102000013165 exonuclease Human genes 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 150000004676 glycans Chemical class 0.000 description 2
- 150000002431 hydrogen Chemical group 0.000 description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
- 125000005647 linker group Chemical group 0.000 description 2
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 2
- 235000021317 phosphate Nutrition 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 230000010076 replication Effects 0.000 description 2
- 108091008146 restriction endonucleases Proteins 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 238000010561 standard procedure Methods 0.000 description 2
- 125000001424 substituent group Chemical group 0.000 description 2
- 150000008163 sugars Chemical class 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 125000002264 triphosphate group Chemical class [H]OP(=O)(O[H])OP(=O)(O[H])OP(=O)(O[H])O* 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- PIINGYXNCHTJTF-UHFFFAOYSA-N 2-(2-azaniumylethylamino)acetate Chemical group NCCNCC(O)=O PIINGYXNCHTJTF-UHFFFAOYSA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- AWGBKZRMLNVLAF-UHFFFAOYSA-N 3,5-dibromo-n,2-dihydroxybenzamide Chemical compound ONC(=O)C1=CC(Br)=CC(Br)=C1O AWGBKZRMLNVLAF-UHFFFAOYSA-N 0.000 description 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- 150000005007 4-aminopyrimidines Chemical class 0.000 description 1
- XZLIYCQRASOFQM-UHFFFAOYSA-N 5h-imidazo[4,5-d]triazine Chemical compound N1=NC=C2NC=NC2=N1 XZLIYCQRASOFQM-UHFFFAOYSA-N 0.000 description 1
- BXJHWYVXLGLDMZ-UHFFFAOYSA-N 6-O-methylguanine Chemical compound COC1=NC(N)=NC2=C1NC=N2 BXJHWYVXLGLDMZ-UHFFFAOYSA-N 0.000 description 1
- ZAOGIVYOCDXEAK-UHFFFAOYSA-N 6-n-methyl-7h-purine-2,6-diamine Chemical compound CNC1=NC(N)=NC2=C1NC=N2 ZAOGIVYOCDXEAK-UHFFFAOYSA-N 0.000 description 1
- 101100459438 Caenorhabditis elegans nac-1 gene Proteins 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 102100033029 Carbonic anhydrase-related protein 11 Human genes 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 108010017826 DNA Polymerase I Proteins 0.000 description 1
- 102000004594 DNA Polymerase I Human genes 0.000 description 1
- 101100321669 Fagopyrum esculentum FA02 gene Proteins 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 101000867841 Homo sapiens Carbonic anhydrase-related protein 11 Proteins 0.000 description 1
- 101001075218 Homo sapiens Gastrokine-1 Proteins 0.000 description 1
- PWKSKIMOESPYIA-BYPYZUCNSA-N L-N-acetyl-Cysteine Chemical compound CC(=O)N[C@@H](CS)C(O)=O PWKSKIMOESPYIA-BYPYZUCNSA-N 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 108020004711 Nucleic Acid Probes Proteins 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- BELBBZDIHDAJOR-UHFFFAOYSA-N Phenolsulfonephthalein Chemical compound C1=CC(O)=CC=C1C1(C=2C=CC(O)=CC=2)C2=CC=CC=C2S(=O)(=O)O1 BELBBZDIHDAJOR-UHFFFAOYSA-N 0.000 description 1
- 239000013616 RNA primer Substances 0.000 description 1
- 230000004570 RNA-binding Effects 0.000 description 1
- 108020004682 Single-Stranded DNA Proteins 0.000 description 1
- 108010006785 Taq Polymerase Proteins 0.000 description 1
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 1
- 229920004892 Triton X-102 Polymers 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 1
- 229960005305 adenosine Drugs 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 229910021538 borax Inorganic materials 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 238000012875 competitive assay Methods 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- RGWHQCVHVJXOKC-SHYZEUOFSA-J dCTP(4-) Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)C1 RGWHQCVHVJXOKC-SHYZEUOFSA-J 0.000 description 1
- NHVNXKFIZYSCEB-XLPZGREQSA-N dTTP Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)C1 NHVNXKFIZYSCEB-XLPZGREQSA-N 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- UQGFMSUEHSUPRD-UHFFFAOYSA-N disodium;3,7-dioxido-2,4,6,8,9-pentaoxa-1,3,5,7-tetraborabicyclo[3.3.1]nonane Chemical compound [Na+].[Na+].O1B([O-])OB2OB([O-])OB1O2 UQGFMSUEHSUPRD-UHFFFAOYSA-N 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- MOTZDAYCYVMXPC-UHFFFAOYSA-N dodecyl hydrogen sulfate Chemical compound CCCCCCCCCCCCOS(O)(=O)=O MOTZDAYCYVMXPC-UHFFFAOYSA-N 0.000 description 1
- 229940043264 dodecyl sulfate Drugs 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- DEFVIWRASFVYLL-UHFFFAOYSA-N ethylene glycol bis(2-aminoethyl)tetraacetic acid Chemical compound OC(=O)CN(CC(O)=O)CCOCCOCCN(CC(O)=O)CC(O)=O DEFVIWRASFVYLL-UHFFFAOYSA-N 0.000 description 1
- 229910052736 halogen Inorganic materials 0.000 description 1
- 150000002367 halogens Chemical class 0.000 description 1
- 125000000623 heterocyclic group Chemical group 0.000 description 1
- 238000001114 immunoprecipitation Methods 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 238000011901 isothermal amplification Methods 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- WAHQBNXSPALNEA-UHFFFAOYSA-L lithium succinate Chemical compound [Li+].[Li+].[O-]C(=O)CCC([O-])=O WAHQBNXSPALNEA-UHFFFAOYSA-L 0.000 description 1
- 229960004254 lithium succinate Drugs 0.000 description 1
- YFVGRULMIQXYNE-UHFFFAOYSA-M lithium;dodecyl sulfate Chemical compound [Li+].CCCCCCCCCCCCOS([O-])(=O)=O YFVGRULMIQXYNE-UHFFFAOYSA-M 0.000 description 1
- 238000004020 luminiscence type Methods 0.000 description 1
- JWILWRLEBBNTFH-UOWFLXDJSA-N methyl (2r,3r,4r)-2,3,4,5-tetrahydroxypentanoate Chemical compound COC(=O)[C@H](O)[C@H](O)[C@H](O)CO JWILWRLEBBNTFH-UOWFLXDJSA-N 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 239000002062 molecular scaffold Substances 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 230000018791 negative regulation of catalytic activity Effects 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 230000036963 noncompetitive effect Effects 0.000 description 1
- 239000002853 nucleic acid probe Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 229960003531 phenolsulfonphthalein Drugs 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 150000008300 phosphoramidites Chemical class 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 230000000379 polymerizing effect Effects 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 150000004804 polysaccharides Polymers 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 150000003212 purines Chemical class 0.000 description 1
- 150000003230 pyrimidines Chemical class 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000003362 replicative effect Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 229920002477 rna polymer Polymers 0.000 description 1
- 229930195734 saturated hydrocarbon Natural products 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 235000010339 sodium tetraborate Nutrition 0.000 description 1
- 239000004328 sodium tetraborate Substances 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6844—Nucleic acid amplification reactions
- C12Q1/6865—Promoter-based amplification, e.g. nucleic acid sequence amplification [NASBA], self-sustained sequence replication [3SR] or transcription-based amplification system [TAS]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6806—Preparing nucleic acids for analysis, e.g. for polymerase chain reaction [PCR] assay
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Wood Science & Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Analytical Chemistry (AREA)
- Biotechnology (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Physics & Mathematics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Ultra Sonic Daignosis Equipment (AREA)
- Magnetic Resonance Imaging Apparatus (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US9497998P | 1998-07-31 | 1998-07-31 | |
| US60/094,979 | 1998-07-31 | ||
| PCT/US1999/017340 WO2000006779A1 (en) | 1998-07-31 | 1999-07-30 | Reversible inhibiting probes |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2002521070A true JP2002521070A (ja) | 2002-07-16 |
| JP2002521070A5 JP2002521070A5 (enExample) | 2007-05-31 |
Family
ID=22248313
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2000562561A Pending JP2002521070A (ja) | 1998-07-31 | 1999-07-30 | 可逆的阻害プローブ |
Country Status (9)
| Country | Link |
|---|---|
| US (3) | US6297365B1 (enExample) |
| EP (1) | EP1100972B1 (enExample) |
| JP (1) | JP2002521070A (enExample) |
| AT (1) | ATE330031T1 (enExample) |
| AU (1) | AU759915B2 (enExample) |
| CA (1) | CA2336539A1 (enExample) |
| DE (1) | DE69931928T2 (enExample) |
| ES (1) | ES2265688T3 (enExample) |
| WO (1) | WO2000006779A1 (enExample) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2010090103A (ja) * | 2008-02-13 | 2010-04-22 | Gene Design Inc | 新規オリゴヌクレオチド誘導体及びそれから成るＮＦ−κＢデコイ |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2316571A3 (en) | 1998-05-01 | 2011-07-27 | Gen-Probe Incorporated | Automated diagnostic analyzer and method |
| US8337753B2 (en) * | 1998-05-01 | 2012-12-25 | Gen-Probe Incorporated | Temperature-controlled incubator having a receptacle mixing mechanism |
| US6297365B1 (en) * | 1998-07-31 | 2001-10-02 | Gen-Probe Incorporated | Decoy probes |
| US7923205B2 (en) * | 2000-08-25 | 2011-04-12 | Toshikazu Shiba | Method for protecting personal information |
| US6794141B2 (en) | 2000-12-22 | 2004-09-21 | Arcturus Bioscience, Inc. | Nucleic acid amplification |
| WO2002072889A2 (en) * | 2001-01-12 | 2002-09-19 | Applera Corporation | Methods and compositions for microarray control |
| EP1373574A4 (en) | 2001-03-30 | 2007-01-03 | Ge Healthcare Bio Sciences Ab | BIOPUCES ANALYSIS OF SIMPLE POLYMORPHISMS NUCL OTIDE |
| CA2477670A1 (en) * | 2002-03-15 | 2003-09-25 | Arcturus Bioscience, Inc. | Improved nucleic acid amplification |
| WO2007062495A1 (en) * | 2005-11-30 | 2007-06-07 | Roy Rabindranauth Sooknanan | Selective terminal tagging of nucleic acids |
| US20080274458A1 (en) * | 2007-05-01 | 2008-11-06 | Latham Gary J | Nucleic acid quantitation methods |
| EP2175999B1 (en) | 2007-06-21 | 2017-01-04 | Gen-Probe Incorporated | Receptacles for use in performing processes |
| CA2964559C (en) | 2007-11-27 | 2020-01-14 | Bio-Rad Laboratories, Inc. | Reduced inhibition of one-step rt-pcr |
| EP2391452B1 (en) | 2009-01-30 | 2015-06-17 | Gen-Probe Incorporated | Systems and methods for detecting a signal and applying thermal energy to a signal transmission element |
| US8916362B2 (en) | 2009-11-23 | 2014-12-23 | Swift Biosciences, Inc. | Devices comprising a polynucleotide to extend single stranded target molecules |
| US20200123598A1 (en) * | 2017-06-20 | 2020-04-23 | Ulisse Biomed S.P.A. | Molecular fingerprinting methods to detect and genotype dna targets through polymerase chain reaction |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1996041010A1 (en) * | 1995-06-07 | 1996-12-19 | Nexstar Pharmaceuticals, Inc. | Nucleic acid ligands that bind to and inhibit dna polymerases |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4720385A (en) * | 1983-03-29 | 1988-01-19 | Miles Laboratories, Inc. | Protein compositions substantially free from infectious agents |
| US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
| US5089386A (en) * | 1987-09-11 | 1992-02-18 | Gene-Trak Systems | Test for listeria |
| CA2013317A1 (en) | 1989-04-17 | 1990-10-17 | Fred T. Oakes | Diagnostic kit, primer composition and their use for replication or detection of nucleic acids |
| US5043272A (en) | 1989-04-27 | 1991-08-27 | Life Technologies, Incorporated | Amplification of nucleic acid sequences using oligonucleotides of random sequence as primers |
| ATE282716T1 (de) | 1989-07-11 | 2004-12-15 | Gen Probe Inc | Verfahren zur amplifikation von nukleinsäuresequenzen |
| US5766849A (en) * | 1989-07-11 | 1998-06-16 | Gen-Probe Incorporated | Methods of amplifying nucleic acids using promoter-containing primer sequence |
| US5215899A (en) * | 1989-11-09 | 1993-06-01 | Miles Inc. | Nucleic acid amplification employing ligatable hairpin probe and transcription |
| US5427930A (en) | 1990-01-26 | 1995-06-27 | Abbott Laboratories | Amplification of target nucleic acids using gap filling ligase chain reaction |
| HU218095B (hu) | 1990-05-01 | 2000-05-28 | Amgen Inc. | Eljárás átvitt szennyeződések csökkentésére, amplifikációs eljárásokban |
| US5811533A (en) * | 1990-06-11 | 1998-09-22 | Nexstar Pharmaceuticals, Inc. | High-affinity oligonucleotide ligands to vascular endothelial growth factor (VEGF) |
| US5270184A (en) | 1991-11-19 | 1993-12-14 | Becton, Dickinson And Company | Nucleic acid target generation |
| US5567583A (en) | 1991-12-16 | 1996-10-22 | Biotronics Corporation | Methods for reducing non-specific priming in DNA detection |
| CA2135073C (en) * | 1992-05-06 | 2002-11-19 | Daniel L. Kacian | Nucleic acid sequence amplification method, composition and kit |
| GB9211979D0 (en) | 1992-06-05 | 1992-07-15 | Buchard Ole | Uses of nucleic acid analogues |
| US5338671A (en) * | 1992-10-07 | 1994-08-16 | Eastman Kodak Company | DNA amplification with thermostable DNA polymerase and polymerase inhibiting antibody |
| US5861273A (en) * | 1993-12-21 | 1999-01-19 | Celtrix Phamraceuticals, Inc. | Chromosomal expression of heterologous genes in bacterial cells |
| WO1996002668A1 (en) * | 1994-07-15 | 1996-02-01 | Azco Nobel N.V. | Use of rna polymerase to improve nucleic acid amplification process |
| GB2293238A (en) * | 1994-09-13 | 1996-03-20 | Inceltec Ltd | Primers for replication and/or amplification reactions |
| EP0912767B1 (en) | 1996-07-16 | 2006-09-13 | Gen-Probe Incorporated | Methods for detecting and amplifying nucleic acid sequences using modified oligonucleotides having increased target specific tm |
| US6297365B1 (en) * | 1998-07-31 | 2001-10-02 | Gen-Probe Incorporated | Decoy probes |
| US6279365B1 (en) * | 2000-06-12 | 2001-08-28 | Shao-Chien Tseng | Cold forging forming method for three-dimensional hollow article |
-
1999
- 1999-07-30 US US09/365,121 patent/US6297365B1/en not_active Expired - Lifetime
- 1999-07-30 ES ES99937681T patent/ES2265688T3/es not_active Expired - Lifetime
- 1999-07-30 DE DE69931928T patent/DE69931928T2/de not_active Expired - Lifetime
- 1999-07-30 AT AT99937681T patent/ATE330031T1/de not_active IP Right Cessation
- 1999-07-30 AU AU52467/99A patent/AU759915B2/en not_active Ceased
- 1999-07-30 CA CA002336539A patent/CA2336539A1/en not_active Abandoned
- 1999-07-30 EP EP99937681A patent/EP1100972B1/en not_active Expired - Lifetime
- 1999-07-30 WO PCT/US1999/017340 patent/WO2000006779A1/en not_active Ceased
- 1999-07-30 JP JP2000562561A patent/JP2002521070A/ja active Pending
-
2001
- 2001-05-29 US US09/867,193 patent/US6602668B2/en not_active Expired - Fee Related
-
2003
- 2003-02-27 US US10/375,623 patent/US7122316B2/en not_active Expired - Fee Related
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1996041010A1 (en) * | 1995-06-07 | 1996-12-19 | Nexstar Pharmaceuticals, Inc. | Nucleic acid ligands that bind to and inhibit dna polymerases |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2010090103A (ja) * | 2008-02-13 | 2010-04-22 | Gene Design Inc | 新規オリゴヌクレオチド誘導体及びそれから成るＮＦ−κＢデコイ |
Also Published As
| Publication number | Publication date |
|---|---|
| DE69931928T2 (de) | 2007-01-04 |
| EP1100972A1 (en) | 2001-05-23 |
| CA2336539A1 (en) | 2000-02-10 |
| WO2000006779A1 (en) | 2000-02-10 |
| US6297365B1 (en) | 2001-10-02 |
| AU759915B2 (en) | 2003-05-01 |
| US6602668B2 (en) | 2003-08-05 |
| DE69931928D1 (de) | 2006-07-27 |
| US20020038016A1 (en) | 2002-03-28 |
| EP1100972B1 (en) | 2006-06-14 |
| US20030157547A1 (en) | 2003-08-21 |
| US7122316B2 (en) | 2006-10-17 |
| AU5246799A (en) | 2000-02-21 |
| ATE330031T1 (de) | 2006-07-15 |
| ES2265688T3 (es) | 2007-02-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US10704042B2 (en) | Ligation-based RNA amplification | |
| JP3085409B2 (ja) | 標的核酸配列の検出方法およびそのための試薬キット | |
| EP0676476B1 (en) | Isothermal strand displacement nucleic acid amplification | |
| US5786183A (en) | Methods of enhancing nucleic acid amplification | |
| CA2734514C (en) | Self-avoiding molecular recognition systems in dna amplification | |
| US6025133A (en) | Promoter-sequestered oligonucleoside and method of use | |
| JP2002521070A (ja) | 可逆的阻害プローブ | |
| JP2005536193A (ja) | 少量のポリヌクレオチドを濃縮する方法 | |
| JP2006020649A (ja) | バックグランドノイズの減少を伴う液相核酸サンドイッチアッセイ | |
| WO1993022461A1 (en) | Nucleic acid sequence amplification method, composition and kit | |
| JPH08205894A (ja) | 核酸の高感度検出方法 | |
| US20090023151A1 (en) | Method For The Labeling And Detection Of Small Polynucleotides | |
| JP2024003255A (ja) | Ｈｅｖ核酸を検出するための組成物および方法 | |
| EP2352846B1 (en) | Rna detection method | |
| JP2006523460A (ja) | 試料中のｓａｒｓコロナウイルスの存在を決定するための組成物および方法 | |
| JP2008514236A (ja) | Ｈｉｖ−１を検出しそして定量するためのアッセイ | |
| JPH06501157A (ja) | 核酸の高感度検出方法 | |
| AU711448B2 (en) | Oligonucleotide probes and methods for detecting streptococcus pneumoniae | |
| JP2023510395A (ja) | 標的ポリヌクレオチドを単離するための組成物、キットおよび方法 | |
| US20020051983A1 (en) | Detection of amplified products in nucleic acid assays following nuclease treatment | |
| WO2009029875A1 (en) | Method for the labeling and detection of small polynucleotides |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20060703 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20070405 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20090817 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20091117 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20091125 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20100118 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20100125 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20100419 |